<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04773730</url>
  </required_header>
  <id_info>
    <org_study_id>regional block</org_study_id>
    <nct_id>NCT04773730</nct_id>
  </id_info>
  <brief_title>Quadratus Lumborum Block Type 2 Versus Posterior Transversus Abdominus Plane Block</brief_title>
  <acronym>quadratus</acronym>
  <official_title>A Comparative Study Between Quadratus Lumborum Block Type 2 and Posterior Transversus Abdominus Plane Block for Analgesia After Cesarean Delivery Under Spinal Anesthesia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mansoura University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mansoura University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This patient population are at risk of adverse effects secondary to inadequate pain&#xD;
      management such as inadequate maternal bonding and late ambulation.&#xD;
&#xD;
      Regional analgesia is preferred due to their opioid sparing effects and reduction in related&#xD;
      adverse effects but the analgesia from these blocks is not known which one is superior to the&#xD;
      other in the context of cesarean section&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The aim of this study is to compare the effect of posterior transversus abdominus plane block&#xD;
      and quadratus lumborum type 2 for cesarean delivery.&#xD;
&#xD;
      The transversus abdominus plane(TAP) block provides sensory block from T6 to L1 for lower&#xD;
      abdominal surgeries.&#xD;
&#xD;
      Quadratous lumborum type 2 block, the injection is posterior to the quadratus lumborum&#xD;
      muscle. This method has the advantage of a more superficial point of injection with better&#xD;
      ultrasonographic resolution.&#xD;
&#xD;
      Only one RCT was done in this context by Kalpana Verma and his colleagues comparing quadratus&#xD;
      lumborum type 2 and posterior transversus abdominus plane block. That shows marked&#xD;
      discrepancy with time to first analgesic request from the quadratus lumborum block in other&#xD;
      abdominal surgeries&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 15, 2021</start_date>
  <completion_date type="Anticipated">May 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">March 1, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>patients will be randomly allocated via sealed opaque envelop into 2 groups of 50 patients each; Posterior transversus abdominus block (TAP) group and Quadratus lumborum block type 2 is the second group (QLB)group</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>pain score assessment will be done by an anesthetist who is not involved in randomization or in the anesthetic technique</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>The analgesic duration</measure>
    <time_frame>within 24 hours after the surgery</time_frame>
    <description>the time measured from finishing the block till the first request of analgesia by the patient</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Postoperative pain at rest</measure>
    <time_frame>immediately and 1,2,3,4hour at postanesthesia care unit, then in the surgical ward at 6,8,10,12,18 and 24 h</time_frame>
    <description>100 centimetres visual analog scale (VAS) for pain, where zero is equal to no pain and hundred indicates the worst possible pain</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative pain on movement (attempted hip flexion) or coughing</measure>
    <time_frame>immediately and 1,2,3,4hour at postanesthesia care unit, then in the surgical ward at 6,8,10,12,18 and 24 h</time_frame>
    <description>100 centimetres visual analog scale (VAS) for pain, where zero is equal to no pain and hundred indicates the worst possible pain</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient satisfaction</measure>
    <time_frame>24 hours after surgery</time_frame>
    <description>poor= 1, fair = 2, good = 3, excellent = 4</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heart rate</measure>
    <time_frame>at 1st, 2nd, 3rd, 4th, 10th, 16th and 22nd hours postoperatively</time_frame>
    <description>beat per minute</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Non-invasive blood pressure</measure>
    <time_frame>at 1st, 2nd, 3rd, 4th, 10th, 16th and 22nd hours postoperatively</time_frame>
    <description>mmHg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total postoperative analgesic consumption of of ketolac, paracetamol and fentanyl</measure>
    <time_frame>within the first 24 hours after surgery</time_frame>
    <description>Patients with visual analog scale more than 30 will receive 30 mg of intravenous ketolac in addition to 1gm paracetamol which will be repeated every 8 hours intravenous infusion of every 8 hours. Intravenous administration of fentanyl bolus doses of 0.5 µg per kg per dose will be given if the visual analog scale remains more than 30</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative nausea and vomiting</measure>
    <time_frame>within 24 hours after surgery</time_frame>
    <description>0= none, 1= mild, 2= moderate and 3= sever</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative lower limb weakness</measure>
    <time_frame>within 24 hours after surgery</time_frame>
    <description>reported by the patient during her first walk after surgery</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Regional Block</condition>
  <arm_group>
    <arm_group_label>Posterior transversus abdominus block</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>After the surgery end and while the patient in the supine position, with the side to be blocked is elevated&#xD;
A 12-14 MHz linear array transducer will be placed transversely between the iliac crest and costal margin then slided from medial-lateral to visualize the posterior most part of the external oblique, internal oblique, and transversus abdominus muscles&#xD;
Then 20 mL of bupivacaine0.25% will be injected between the transverses abdominus muscle and the fascia deep to the internal oblique muscle&#xD;
The same steps will be repeated on the other side</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Quadratus lumborum block type 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>After the surgery end and while the patient in the supine position, with the side to be blocked is elevated&#xD;
A2-5 MHz curved array transducer will be placed at the level of the antero-superior iliac spine then the external oblique muscle will be followed posterolaterally until its posterior border will be visualized The probe will be tilted down to identify a bright hyperechoic line After that 20 mL of bupivacaine 0.25% will be injected under direct visualization on the posterior surface of quadrates lumborum muscle&#xD;
The same steps will be repeated on the other side</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Posterior transversus abdominus plane block</intervention_name>
    <description>Twenty mL of bupivacaine 0.25% will be injected in the plane between the transverses abdominus muscle and the fascia deep to the internal oblique muscle on each side</description>
    <arm_group_label>Posterior transversus abdominus block</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Quadratus lumborum block type 2</intervention_name>
    <description>Twenty mL of bupivacaine 0.25% will be injected on the posterior surface of quadrates lumborum muscle on each side</description>
    <arm_group_label>Quadratus lumborum block type 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  American Society of Anesthesiologists physical status II parturient.&#xD;
&#xD;
          -  Singleton pregnancies with a gestation of at least 37 weeks.&#xD;
&#xD;
          -  Patients undergoing spinal anesthesia for cesarean deliveryvia a Pfannenstiel incision&#xD;
             with exteriorization of the uterus.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Age &lt; 19 or &gt; 40 years.&#xD;
&#xD;
          -  Height&lt;150 cm, weight &lt; 60 kg, body mass index (BMI) ≥35 kg/m2.&#xD;
&#xD;
          -  Inability to comprehend or participatein pain scoring system.&#xD;
&#xD;
          -  Contraindications to spinal anesthesia (Coagulopathy, increased intracranial pressure,&#xD;
             or local skin infection).&#xD;
&#xD;
          -  Hypersensitivity to any drugused in the study.&#xD;
&#xD;
          -  Hypertensive disorders of pregnancy.&#xD;
&#xD;
          -  Renal impairment or other contraindication to non-steroidal anti-inflammatory drugs.&#xD;
&#xD;
          -  Significant cardiovascular, renal or hepatic abnormalities.&#xD;
&#xD;
          -  Patients with history of opoid intake, drug abusers, psychiatric patients.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Parturient Female patients</gender_description>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Maha Ahmed Abozeid, MD</last_name>
    <role>Study Director</role>
    <affiliation>Faculty of Medicine - Mansoura University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Maha Ahmed Abozeid, MD</last_name>
    <phone>02-01019216192</phone>
    <email>mahazed@mans.edu.eg</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mohamed Younis Makharita, MD</last_name>
    <phone>00201023092930</phone>
    <email>m_younis24@yahoo.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>El Mansoura</name>
      <address>
        <city>El Mansoura</city>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maha A Abozeid, MD</last_name>
      <phone>00201019216192</phone>
      <email>mahazed@mans.edu.eg</email>
    </contact>
    <contact_backup>
      <last_name>Mohamed Y Makharita, MD</last_name>
      <phone>00201023092930</phone>
      <email>m_younis24@yahoo.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>February 20, 2021</study_first_submitted>
  <study_first_submitted_qc>February 24, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 26, 2021</study_first_posted>
  <last_update_submitted>March 19, 2021</last_update_submitted>
  <last_update_submitted_qc>March 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mansoura University</investigator_affiliation>
    <investigator_full_name>maha abou-zeid</investigator_full_name>
    <investigator_title>Assistant professor of anesthesia and surgical intensive care</investigator_title>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

